

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- have one of the following confirmed locally advanced (unresectable) or metastatic solid tumor: Head and neck cancer, cervical cancer, non-small cell lung cancer, melanoma, ovarian cancer, HPV positive anogenital cancer HPV positive anogenital cancers

Exclusion Criteria:

- undergoing anticancer therapy with curative intent

Conditions & Interventions

Interventions:

Diagnostic Test: Tumor and HLA Profiling

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), anal, Cervical, genital, Head and Neck, HPV16, Melanoma, Non Small Cell Lung, Ovarian, Solid Tumor

More Information

Description: The purpose of this screening study is to collect samples to conduct the testing of specific human leukocyte antigen (HLA). TScan Therapeutics is developing cellular therapies across multiple solid tumors in which the eligibility criteria require that participants have specific HLA types. The results from this screening study will be used to determine if participants meet the eligibility criteria and could potentially be enrolled in a future TScan treatment study.

Study Contact: Jordan Marth - marth137@umn.edu

Principal Investigator: Benjamin Manning

IRB

Number: STUDY00019929

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.